Sanofi and Regeneron Report Phase 3 LIBERTY CD Results for Dupixent in Crohn's Disease

Sanofi and Regeneron today announced results from the Phase 3 LIBERTY CD trial evaluating Dupixent (dupilumab) in patients with moderate-to-severe Crohn's disease. The trial met its primary endpoint, demonstrating a significantly higher rate of clinical remission compared to placebo at week 12.